Search

Displaying results 2481 - 2490 of 7600 in total
  1. Drug

    Leridistim

    go.drugbank.com/drugs/DB15095
    Investigational

    Leridistim is under investigation in clinical trial NCT00004215 (Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia).

  2. Drug

    Capromorelin

    go.drugbank.com/drugs/DB15205
    Investigational

    Capromorelin is under investigation in clinical trial NCT00527046 (Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults).

  3. Drug

    Factor XIII (human)

    go.drugbank.com/drugs/DB12909
    ApprovedInvestigational

    For people with congenital deficiency or mutation of Factor XIII, a rare bleeding disorder, exogenous replacement of this key coagulation factor is essential for management and prevention of bleeding episodes … Factor XIII (human) is a heat-treated, lyophilized concentrate of coagulation factor XIII, an endogenous enzyme responsible for the crosslinking of fibrin and an essential component of the coagulation

  4. Drug

    Cinoxacin

    go.drugbank.com/drugs/DB00827
    ApprovedWithdrawn

    Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Linzagolix

    go.drugbank.com/drugs/DB17083
    ApprovedInvestigational

    [A253667] Linzagolix was approved for use in the European Union in June 2022 for the management of symptoms caused by uterine fibroids.[L43627] … It has been studied for the treatment of estrogen-dependent conditions such as uterine fibroids and endometriosis.

  6. Drug

    Fesoterodine

    go.drugbank.com/drugs/DB06702
    Approved

    Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.

    Categories: Drugs for Urinary Frequency and Incontinence
  7. Drug

    Zidebactam

    go.drugbank.com/drugs/DB13090
    Approved

    [L63350,L63932] The combination is aimed at multidrug-resistant Gram-negative infections, a group for which treatment options are limited and where resistance to carbapenems has narrowed the available … [L63932] Wockhardt announced FDA approval of the cefepime-zidebactam combination on May 30, 2026, for adults with complicated urinary tract infections, including pyelonephritis, caused by designated

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  8. Drug

    Mumps virus strain B level jeryl lynn live antigen

    go.drugbank.com/drugs/DB10316
    ApprovedInvestigational

    Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease.

    Mixtures: Sterile Diluent for M-M-R II
  9. Drug

    Revakinagene taroretcel

    go.drugbank.com/drugs/DB05344
    ApprovedInvestigational

    [A265115] On March 6, 2025, FDA approved revakinagene taroretcel for the treatment of idiopathic macular telangiectasia type 2. … encapsulated cell-based gene therapy that contains 200,000 to 440,000 allogeneic retinal pigment epithelial cells expressing recombinant human ciliary neurotropic factor (rhCNTF) (NTC-201-6A cell line) for

  10. Drug

    Cyclobenzaprine

    go.drugbank.com/drugs/DB00924
    ApprovedInvestigational

    Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961[A185039] and has been available for human use since 1977. … [A184982] It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.